Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
Hims & Hers falls after FDA crackdown on unapproved weight-loss drugs
Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in compounding and that it has already warned companies marketing unapproved retatrutide directly to consumers.
Hims & Hers: A Healthcare Behemoth In The Making
Hims & Hers Health is building a vertically integrated consumer-health distribution platform, with value driven by its scalable engine rather than individual products. HIMS demonstrates accelerating growth, with multiple product lines surpassing $100M ARR and rapid vertical launches, supporting a strong buy rating and a $111 price target for 2026. Q2 results showed robust revenue growth (38%) and strong Q3 guidance (47-50%), despite margin compression from branded weight-loss and international expansion.
Hims & Hers Is Growing Into Something Much Bigger
Hims & Hers approaches 3 million subscribers as U.S. growth reaccelerates and international markets emerge as a meaningful second growth engine. International revenue reached $131 million, while testosterone is approaching Hims' sixth U.S. specialty above a $100 million annual run rate. Gross margin fell to 64%, while Q2 free cash flow reached negative $68 million, making operating leverage the critical next test.
HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally?
Hims & Hers' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.
Hims & Hers: Buying The Margin Dip
Hims & Hers Health (HIMS) is rated a buy at current levels, driven by robust international expansion and product innovation. International revenue surged over 17-fold YoY to $131M, with Eucalyptus acquisition and new markets fueling growth and future $600M+ 2026 target. AI investment aims to reduce customer-support costs and improve retention, with payback expected in 12–18 months as in-house capabilities scale.
Watch CNBC's full interview with Hims & Hers CEO Andrew Dudum
In an exclusive interview, Hims & Hers CEO Andrew Dudum sits down with Squawk Box Co-Anchor Andrew Ross Sorkin and shares his perspective on how AI can transform healthcare, the company's transition from compound to brand name GLP-1s, and his vision to bring down the cost of healthcare.
Hims & Hers Health's Next Act: Making Its Own Drugs Again
I'm maintaining my buy on Hims & Hers Health, and the reasoning has moved past the branded GLP-1 transition that drove my May upgrade. 2Q revenue grew 38% to $753.2 million and management raised the full-year outlook to $3.1–$3.3 billion, while gross margin fell six points sequentially to 64%. HIMS is now a distribution layer for branded weight-loss drugs, a business that buys revenue with margin, and the EBITDA guide shows the bill.
Hims & Hers: The Guidance Raise Doesn't Fix The Margin Problem
Hims & Hers Health delivered strong Q2 2026 revenue growth but suffered margin compression and negative free cash flow. I rate HIMS a Sell, as the raised revenue guidance is offset by declining gross margins and a stagnant adjusted EBITDA outlook. The shift to branded GLP-1 weight-loss drugs and international expansion are driving higher costs and complicating the profitability story.
